NOVALIS LIFESCIENCES
Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis works with a diversified group of project-based specialists leading in their respective life science fields
NOVALIS LIFESCIENCES
Founded:
2017-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Google Apps For Business Typekit Squarespace
Similar Organizations
PolyCore Therapeutics
PolyCore Therapeutics’ team of life sciences scientists is dedicated to developing breakthrough treatments for CNS Diseases.
Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-23 | eTheRNA immunotherapies | Novalis LifeSciences investment in Series B - eTheRNA immunotherapies | 39 M EUR |
| 2022-07-28 | Animol Discovery | Novalis LifeSciences investment in Series B - Animol Discovery | 34 M USD |
| 2022-07-27 | Enko Chem | Novalis LifeSciences investment in Series C - Enko Chem | 70 M USD |
| 2022-06-03 | Vizgen | Novalis LifeSciences investment in Series C - Vizgen | 85.2 M USD |
| 2022-03-08 | Sherlock Biosciences | Novalis LifeSciences investment in Series B - Sherlock Biosciences | 80 M USD |
| 2022-01-18 | Ori Biotech | Novalis LifeSciences investment in Series B - Ori Biotech | 100 M USD |
| 2021-12-21 | SkylineDx | Novalis LifeSciences investment in Venture Round - SkylineDx | N/A |
| 2021-09-14 | AgBiome | Novalis LifeSciences investment in Series D - AgBiome | 116 M USD |
| 2021-04-07 | Vizgen | Novalis LifeSciences investment in Series B - Vizgen | 37 M USD |
| 2020-07-29 | Cerevel Therapeutics | Novalis LifeSciences investment in Post-IPO Equity - Cerevel Therapeutics | 320 M USD |